EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria

Ali Haghiri, David J Price, Phoebe Fitzpatrick, Saber Dini, Megha Rajasekhar, Caterina Fanello iD, Joel Tarning iD, James Watson iD, Nicholas J White iD, Julie A Simpson iD

Clinical Pharmacology & Therapeutics · 2023-12 · 114 (6) · 1304-1312

DOI: 10.1002/cpt.3041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 15.09.2023. Verfasst von Ali Haghiri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Austra…. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian National Health and Medical Research Council, Australian Centre for Research Excellence in Malaria Elimination, Wellcome Trust, UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first‐line treatment for severe falciparum malaria. Since 2015, the World Health Organization has recommended individual doses of 3 mg/kg for children weighing < 20 kg. Recently, the US Food and Drug Administration (FDA) has challenged this recommendation, based on a simulated pediatric population, and argued for a lower dose in younger children (2.4 mg/kg). In this study, we performed population pharmacokinetic (PK) modeling of plasma concentration data from 80 children with severe falciparum malaria in the Democratic Republic of Congo who were given 2.4 mg/kg of ARS intravenously. Bayesian hierarchical modeling and a two‐compartment parent drug‐metabolite PK model for ARS were used to describe the population PKs of ARS and its main biologically active metabolite dihydroartemisinin. We then generated a virtual population representative of the target population in which the drug is used and simulated the total first‐dose exposures. Our study shows that the majority of younger children given the lower 2.4 mg/kg dose of intravenous ARS do not reach the same drug exposures as older children above 20 kg. This finding supports withdrawal of the FDA's recent lower ARS dose recommendation as parenteral ARS is an extremely safe and well‐tolerated drug and there is potential for harm from underdosing in this rapidly lethal infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsMalariaMalaria, FalciparumChildHumansAdolescentArtesunateBayes TheoremAdministration, Intravenous

Substanzen

ArtesunateAntimalarials

Autor:innen und Institutionen

  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • School of Engineering, University of Leicester, Leicester, UK.
  • Doherty Institute for Infection and Immunity, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
  • Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, Oxford University, Oxford, UK.
  • Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Caterina Fanello, Joel Tarning, James Watson, Nicholas J White, Julie A Simpson

Förderung

  • Australian National Health and Medical Research Council
  • Australian Centre for Research Excellence in Malaria Elimination
  • Wellcome Trust, UK
  • Wellcome Trust

Zitieren

APA

Haghiri, A., Price, D. J., Fitzpatrick, P., Dini, S., Rajasekhar, M., Fanello, C., Tarning, J., Watson, J., White, N. J., & Simpson, J. A. (2023). Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria. Clinical Pharmacology & Therapeutics, 114(6), 1304-1312. https://doi.org/10.1002/cpt.3041

Vancouver

Haghiri A, Price DJ, Fitzpatrick P, Dini S, Rajasekhar M, Fanello C, et al. Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria. Clinical Pharmacology & Therapeutics. 2023;114(6):1304-1312. doi:10.1002/cpt.3041

BibTeX
@article{Haghiri2023,
  author = {Haghiri, Ali and Price, David J and Fitzpatrick, Phoebe and Dini, Saber and Rajasekhar, Megha and Fanello, Caterina and Tarning, Joel and Watson, James and White, Nicholas J and Simpson, Julie A},
  title = {Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {6},
  pages = {1304--1312},
  doi = {10.1002/cpt.3041}
}
Kostenlos starten →